Summary & Overview
HCPCS E0766: Electrical Stimulation Device for Cancer Treatment
HCPCS Level II code E0766 designates an electrical stimulation device used for cancer treatment, inclusive of all accessories. This device-based therapeutic code is relevant nationally as oncology practices and durable medical equipment suppliers incorporate adjunct electrical stimulation therapies into cancer care pathways. The code matters for billing clarity, coverage determinations, and supply-chain management for outpatient and ambulatory oncology services.
Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of coverage considerations and common payer approaches, benchmarking context where available, and the clinical setting in which the device is most often used. The publication outlines the service classification for billing purposes, typical sites of service, and operational implications for providers and suppliers that bill for device-based cancer therapies.
The report does not provide specific clinical guidance. It summarizes the code purpose, payer landscape, and the kinds of information stakeholders typically consult when assessing coverage and billing workflows for oncology electrical stimulation devices. Data not available in the input are noted where applicable.
Billing Code Overview
HCPCS Level II code E0766 represents an electrical stimulation device used for cancer treatment, including all accessories, any type. The service type is device-based cancer therapy using electrical stimulation, delivered as a durable medical equipment/adjunctive therapeutic device. The typical site of service is outpatient clinics, oncology treatment centers, or other ambulatory care settings where device-based cancer therapies are administered.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A patient with recurrent or metastatic breast cancer receives localized electrical stimulation therapy (E0766) as an adjunct palliative oncologic treatment to reduce tumor-associated pain and improve local control when standard systemic therapies are limited. The patient is a 62-year-old female with stage IV hormone-receptor–positive breast cancer experiencing focal chest wall pain and a superficial lesion accessible for electrode placement. The clinical workflow includes: initial oncology consultation; review of imaging to localize the target lesion; informed consent focused on palliative intent and device-specific risks; placement of external electrodes by a radiation oncologist, medical oncologist, or physical medicine specialist; device programming and delivery of a prescribed stimulation course; documentation of start/stop times, electrode sites, device settings, and patient response; and follow-up visits for efficacy assessment and device-related adverse events. Device supply, accessories, and any reusable components are accounted for under the single HCPCS code E0766.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when billing exclusively for the physician’s interpretation or procedural oversight of the stimulation treatment separate from equipment/supply charges. |